| Cell line name |
MDA-MB-231 NAT1 up |
|---|
| Synonyms |
NAT1 Overexpression |
|---|
| Accession |
CVCL_A9BC |
|---|
| Resource Identification Initiative |
To cite this cell line use: MDA-MB-231 NAT1 up (RRID:CVCL_A9BC) |
|---|
| Comments |
Group: Triple negative breast cancer (TNBC) cell line.
Population: Caucasian.
Characteristics: Transfected with a pcDNA5/FRT derived construct with a NATb promoter driving the expression of NAT1 (NATb/NAT1*4).
Doubling time: 23.4 hours (PubMed=29315819).
Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:7645; NAT1.
Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) (HygR).
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175. |
|---|
| Sequence variations |
- Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
- Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Breast adenocarcinoma (NCIt: C5214) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_0062 (MDA-MB-231) |
|---|
| Sex of cell |
Female |
|---|
| Age at sampling |
51Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=29315819; DOI=10.1002/mc.22779; PMCID=PMC5832614
Marcus W. Stepp, Mark A. Doll, Samantha M. Carlisle, J. Christopher States, David W. Hein;
Genetic and small molecule inhibition of arylamine N-acetyltransferase 1 reduces anchorage-independent growth in human breast cancer cell line MDA-MB-231.
Mol. Carcinog. 57:549-558(2018) PubMed=29964355; DOI=10.1002/mc.22869; PMCID=PMC6353662
Samantha M. Carlisle, Patrick J. Trainor, Mark A. Doll, Marcus W. Stepp, Carolyn M. Klinge, David W. Hein;
Knockout of human arylamine N-acetyltransferase 1 (NAT1) in MDA-MB-231 breast cancer cells leads to increased reserve capacity, maximum mitochondrial capacity, and glycolytic reserve capacity.
Mol. Carcinog. 57:1458-1466(2018) PubMed=32555504; DOI=10.1038/s41598-020-66863-4; PMCID=PMC7299936
Samantha M. Carlisle, Patrick J. Trainor, Kyung U. Hong, Mark A. Doll, David W. Hein;
CRISPR/Cas9 knockout of human arylamine N-acetyltransferase 1 in MDA-MB-231 breast cancer cells suggests a role in cellular metabolism.
Sci. Rep. 10:9804.1-9804.15(2020) |
|---|
| Cross-references |
|---|
| Cell line databases/resources |
cancercelllines; CVCL_A9BC
|
|---|
| Encyclopedic resources |
Wikidata; Q108820872
|
|---|
| Entry history |
|---|
| Entry creation | 23-Sep-2021 |
|---|
| Last entry update | 19-Dec-2024 |
|---|
| Version number | 9 |
|---|
